Separate terms with OR to return results that match either term.
 
Clear All
10,000 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date (Descending) Status
00093-7768-24 00093-7768 Everolimus Everolimus 7.5 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral June 10, 2020 In Use
00703-3216-01 00703-3216 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous March 25, 2020 In Use
00703-3216-81 00703-3216 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous March 5, 2020 In Use
00703-3217-01 00703-3217 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous March 5, 2020 In Use
00703-3213-01 00703-3213 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous July 7, 2020 In Use
00703-3213-81 00703-3213 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous July 7, 2020 In Use
00703-3218-01 00703-3218 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous March 5, 2020 In Use
00703-3218-81 00703-3218 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous March 5, 2020 In Use
00338-0067-01 00338-0067 doxorubicin hydrochloride DOXIL 2.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline INTRAVITREAL, Intravenous Aug. 13, 2019 In Use
00338-0063-01 00338-0063 doxorubicin hydrochloride DOXIL 2.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous Aug. 13, 2019 In Use
00069-0688-03 00069-0688 palbociclib Ibrance 125.0 mg/1 Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 Oral March 30, 2020 In Use
00069-0486-03 00069-0486 Palbociclib Ibrance 100.0 mg/1 Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 Oral March 30, 2020 In Use
73153-0900-01 73153-0900 Lisocabtagene maraleucel BREYANZI Immunotherapy CAR-T CD19 Feb. 5, 2021 In Use
73462-0101-01 73462-0101 Trilaciclib Cosela 300.0 mg/20mL Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 Intravenous Feb. 12, 2021 In Use
00054-0480-13 00054-0480 Everolimus Everolimus 2.5 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral Feb. 12, 2021 In Use
00054-0480-14 00054-0480 Everolimus Everolimus 2.5 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral June 8, 2020 In Use
00054-0481-13 00054-0481 Everolimus Everolimus 5.0 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral Feb. 12, 2021 In Use
00054-0481-14 00054-0481 Everolimus Everolimus 5.0 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral June 8, 2020 In Use
00054-0497-13 00054-0497 Everolimus Everolimus 7.5 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral Feb. 12, 2021 In Use
00054-0497-14 00054-0497 Everolimus Everolimus 7.5 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral June 8, 2020 In Use
00069-0308-01 00069-0308 trastuzumab-qyyp Trazimera 150.0 mg/7.15mL Immunotherapy Monoclonal Antibody HER2 Intravenous March 10, 2021 In Use
72189-0084-24 72189-0084 IMIQUIMOD IMIQUIMOD 12.5 mg/.25g Immunotherapy Immunomodulator Dermatological Agent Topical March 23, 2020 In Use
00143-9606-01 00143-9606 Azacitidine Azacitidine 100.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Intravenous, Subcutaneous June 8, 2020 In Use
00338-0080-01 00338-0080 Doxorubicin Hydrochloride Liposome Doxorubicin Hydrochloride Liposome 2.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous Aug. 15, 2019 In Use
00338-0086-01 00338-0086 Doxorubicin Hydrochloride Liposome Doxorubicin Hydrochloride Liposome 2.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous Aug. 15, 2019 In Use

Found 10,000 results in 6 milliseconds — Export these results